IP Library Granted Patent US 9,387,187
Granted Patent B2
US 9,387,187 · App. 14/263,758 · Granted Jul 12, 2016

Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders

Inventors: Michael Graeber (Lawrenceville, NJ); Janusz Czernielewski (Biot, FR)
Assignee: GALDERMA RESEARCH & DEVELOPMENT
A61K31/192A61K8/362A61K9/0014A61K9/06A61K31/07A61Q17/04A61K31/203A61K47/10A61K47/183A61K47/32A61K47/48784C07C2103/74Y10S514/859
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,387,187
App. No.
14/263,758
Granted
Jul 12, 2016
Kind
B2
Abstract

Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Claims (21)

1. A method for eliciting an early onset of action in regression of inflammatory lesions, regression of non-inflammatory lesions or regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6[-3-(1-adamantyl)]-4-methoxyphenyl-2-naphthoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, wherein said early onset of action occurs by four weeks after treatment begins and is demonstrated by regression of inflammatory lesions, regression of non-inflammatory lesions or regression of total acne lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

2. The method according to claim 1 , wherein the common acne is of moderate to moderately severe intensity.

3. The method according to claim 1 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

4. The method according to claim 1 , wherein the composition comprises a gel.

5. The method according to claim 2 , wherein the composition comprises a gel.

6. A method for eliciting an early onset of action in regression of inflammatory lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, wherein said early onset of action occurs by four weeks after treatment begins and is demonstrated by regression of inflammatory lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

7. The method according to claim 6 , wherein the common acne is of moderate to moderately severe intensity.

8. The method according to claim 6 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

9. The method according to claim 6 , wherein the composition comprises a gel.

10. The method according to claim 7 , wherein the composition comprises a gel.

11. A method for eliciting an early onset of action in regression of non-inflammatory lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6[-3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by four weeks after treatment begins and being demonstrated by regression of non-inflammatory lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

12. The method according to claim 11 , wherein the common acne is of moderate to moderately severe intensity.

13. The method according to claim 11 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hyrdoxide and purified water.

14. The method according to claim 12 , wherein the composition is a gel comprising adapalene, carbomer940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

15. The method according to claim 11 , wherein the composition comprises a gel.

16. The method according to claim 12 , wherein the composition comprises a gel.

17. A method for eliciting an early onset of action in regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by four weeks after treatment begins and being demonstrated by regression of total acne lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

18. The method according to claim 17 , wherein the common acne is of moderate to moderately severe intensity.

19. The method according to claim 17 , wherein the composition comprises a gel.

20. The method according to claim 18 , wherein the composition comprises a gel.

21. The method according to claim 17 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: GRAEBER, MICHAEL; CZERNIELEWSKI, JANUSZ
To: GALDERMA RESEARCH & DEVELOPMENT
Reel/Frame 038349/0485 →
Priority Claims (1)
FR 02 03070 · Mar 12, 2002 · national
Continuity (7)
Continuation 13024681 · Feb 10, 2011
Continuation 12902972 · Oct 12, 2010
Continuation 12437008 · May 7, 2009
Continuation 10937612 · Sep 10, 2004
Continuation PCTEP0303246 · Mar 12, 2003
Provisional Application 60370223 · Apr 8, 2002
Related Publication 20140249232A1 · Sep 4, 2014